Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Systematic review supports etripamil for PSVT treatment

01 Dec 2025 bởi

A systemic review presented at AHA 2025 demonstrates the potential of etripamil nasal spray as a patient-administered therapy for paroxysmal supraventricular tachycardia (PSVT), which may reduce reliance on emergency care.

Systematic review supports etripamil for PSVT treatment

01 Dec 2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-October-2025

01 Dec 2025

New drug applications approved by US FDA as of 1-15 October 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-October-2025

01 Dec 2025

Dapoxetine plus nonpharmacological approach improves lifelong premature ejaculation

30 Nov 2025

Treatment with dapoxetine combined with nonpharmacological interventions is effective in improving sexual function in individuals with lifelong premature ejaculation (LPE), as shown in a study.

Dapoxetine plus nonpharmacological approach improves lifelong premature ejaculation

30 Nov 2025

Prepregnancy metformin use tied to lower risk of hyperemesis gravidarum

30 Nov 2025

Metformin treatment prior to conception is associated with a reduced risk for severe nausea and vomiting during pregnancy, according to new research.

Prepregnancy metformin use tied to lower risk of hyperemesis gravidarum

30 Nov 2025

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

Patients with cirrhosis using calcium channel blockers (CCBs) are not at increased risk of variceal haemorrhage, as reported in a retrospective study.

CCBs not associated with variceal haemorrhage in cirrhosis

29 Nov 2025

Telitacicept reduces proteinuria in adults with IgA nephropathy

29 Nov 2025 bởi

Treatment with telitacicept led to a significant reduction in proteinuria among patients with immunoglobulin A nephropathy (IgAN) compared with placebo, according to a phase III study presented at ASN Kidney Week 2025.

Telitacicept reduces proteinuria in adults with IgA nephropathy

29 Nov 2025

GLP-1 RAs reduce deaths, MACE in at-risk individuals

28 Nov 2025

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) results in a decrease in deaths and major adverse cardiovascular events (MACE) in high-risk patients, reports as study.

GLP-1 RAs reduce deaths, MACE in at-risk individuals

28 Nov 2025

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

28 Nov 2025 bởi

In the post hoc analysis of the phase III PROTECT trial, the non-immunosuppressive dual endothelin angiotensin receptor antagonist sparsentan remains superior to irbesartan for the treatment of immunoglobulin A nephropathy (IgAN).

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

28 Nov 2025

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

28 Nov 2025

Discontinuing treatment with GLP-1RAs before or early into pregnancy in women with obesity may lead to more gestational weight gain and increased risk of preterm delivery, gestational diabetes, and hypertensive disorders of pregnancy, according to a retrospective study.

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

28 Nov 2025

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

27 Nov 2025

In the treatment of patients with chronic kidney disease (CKD) at high risk of progression, a fixed dose combination of balcinrenone and dapagliflozin is well tolerated and results in greater reductions in albuminuria as compared with dapagliflozin alone in reducing albuminuria, according to the phase IIb MIRO-CKD study.

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

27 Nov 2025

Tin tức & Cập nhật

Xem bài viết Dược

Xem

Chuyên ngành:

Systematic review supports etripamil for PSVT treatment

Systematic review supports etripamil for PSVT treatment

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-October-2025

Original-New-Drug-Application-Approvals-by-US-FDA--1-15-October-2025

Dapoxetine plus nonpharmacological approach improves lifelong premature ejaculation

Dapoxetine plus nonpharmacological approach improves lifelong premature ejaculation

Prepregnancy metformin use tied to lower risk of hyperemesis gravidarum

Prepregnancy metformin use tied to lower risk of hyperemesis gravidarum

CCBs not associated with variceal haemorrhage in cirrhosis

CCBs not associated with variceal haemorrhage in cirrhosis

Telitacicept reduces proteinuria in adults with IgA nephropathy

Telitacicept reduces proteinuria in adults with IgA nephropathy

GLP-1 RAs reduce deaths, MACE in at-risk individuals

GLP-1 RAs reduce deaths, MACE in at-risk individuals

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

Sparsentan remains superior to irbesartan for IgAN in post hoc analysis

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

Stopping GLP-1RAs before or shortly after conception ups pregnancy complications

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD

Fixed-dose balcinrenone–dapagliflozin combo works in high-risk CKD